3-methyl-2-(trifluoromethylsulfonyloxy)benzoic acid methyl ester | 145797-53-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-methyl-2-(trifluoromethylsulfonyloxy)benzoic acid methyl ester
• 英文别名: methyl 3-methyl-2-(trifluoromethylsulfonyloxy)benzoate；methyl 2-trifluoromethanesulfonyloxy-3-methylbenzoate；Methyl 3-methyl-2-trifluoromethanesulphonyloxybenzoate
• CAS: 145797-53-1
• 化学式: C₁₀H₉F₃O₅S
• 分子量: 298.24
• InChiKey: IMFWGLMNHIVTSV-UHFFFAOYSA-N

物化性质

• 沸点：
  347.1±42.0 °C(Predicted)
• 密度：
  1.454±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  78
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  3-methyl-2-(trifluoromethylsulfonyloxy)benzoic acid methyl ester 在 manganese(IV) oxide 、 copper(l) iodide 、 lithium aluminium tetrahydride 、 四(三苯基膦)钯 、 palladium 10% on activated carbon 、 氢气 、 四丁基碘化铵 、 三乙胺 作用下， 以 甲醇 、 乙醚 、 二氯甲烷 、 乙酸乙酯 、 乙腈 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 64.0h， 生成 2-(4-methoxyphenethyl)-3-methylbenzaldehyde
  参考文献：
  名称：

  Concise Route to 3-Arylisoquinoline Skeleton by Lewis Acid Catalyzed C(sp³)–H Bond Functionalization and Its Application to Formal Synthesis of (±)-Tetrahydropalmatine

  摘要：

  An expeditious route to furnish an isoquinoline skeleton via hydride shift mediated C-H bond functionalization was developed. In this process, an unusual [1,5]-H shift without the assistance of the adjacent heteroatom took place to produce tetrahydroisoquinoline derivatives in good to excellent chemical yields. The formal synthesis of (+/-)-tetrahydropalmatine was achieved by exploiting this new transformation.

  DOI：

  10.1021/ol300180w
• 作为产物：
  描述：

  2-羟基-3-甲基苯甲酸甲酯 生成 3-methyl-2-(trifluoromethylsulfonyloxy)benzoic acid methyl ester
  参考文献：
  名称：

  Triaromatic compounds and pharmaceutical/cosmetic compositions comprised

  摘要：

  新型具有药用/化妆作用的三芳基化合物的结构式（I）如下：##STR1##，可用于治疗各种疾病状态，无论是人类还是兽医，例如皮肤病、风湿病、呼吸系统疾病、心血管疾病、骨骼疾病和眼科疾病，以及哺乳动物皮肤和毛发状况/疾病的治疗。

  公开号：

  US06150413A1

文献信息

• Carboxamides useful as inhinitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion
  申请人：——

  公开号：US20030109700A1

  公开（公告）日：2003-06-12

  1 Compounds of formula (1) wherein R 2 —C, R 3 —C, R 4 —C or R 5 —C may be replaced by N; and wherein n is 1, 2 or 3; R 1 is aryl, heteroaryl or (aryl or heteroaryl)-lower alkoxy; R 2 , R 3 , R 4 and R 5 are independently hydrogen, lower alkyl, lower alkoxy, halo, trifluoromethyl or cyano; R 6 is (i) or (ii) m is 1, 2 or 3; R 7 is hydrogen, lower alkyl (aryl or heteroaryl)-lower alkyl, lower alkoxy, (aryl or heteroaryl)-lower alkoxy, hydroxy, oxo, lower alkylenedioxy or lower alkanoyloxy; W is O, S or NR 8 ; R 8 is —COR a , (iii), —COOR d , —SO 2 R e , hydrogen, optionally substituted lower alkyl, aryl, heteroaryl or (aryl or heteroaryl)-lower alkyl; R a , R d and R e , are independently optionally substituted lower alkyl, cycloalkyl, adamantyl, aryl, heteroaryl or (aryl or heteroaryl)-lower alkyl; R b and R c are independently hydrogen, cycloalkyl, optionally substituted lower alkyl, aryl, heteroaryl or (aryl or heteroaryl) lower alkyl; or R b and R c together represent lower alkylene; and pharmaceutically acceptable salts thereof; and enantiomers thereof; which are useful as inhibitors of microsomal triglyceride transfer protein (MTP) and of apolipoprotein B (apoB) secretion.

  式（1）的化合物中，其中R2—C，R3—C，R4—C或R5—C可以被N取代；其中n为1、2或3；R1为芳基，杂环芳基或（芳基或杂环芳基）-较低烷氧基；R2、R3、R4和R5独立地为氢、较低烷基、较低烷氧基、卤素、三氟甲基或氰基；R6为（i）或（ii）m为1、2或3；R7为氢、较低烷基（芳基或杂环芳基）-较低烷基、较低烷氧基、（芳基或杂环芳基）-较低烷氧基、羟基、氧代、较低烷二氧基或较低烷酰氧基；W为O、S或NR8；R8为—CORa、（iii）、—COORd、—SO2Re、氢、可选择取代的较低烷基、芳基、杂环芳基或（芳基或杂环芳基）-较低烷基；Ra、Rd和Re独立地为可选择取代的较低烷基、环烷基、脱氢脂肪基、芳基、杂环芳基或（芳基或杂环芳基）-较低烷基；Rb和Rc独立地为氢、环烷基、可选择取代的较低烷基、芳基、杂环芳基或（芳基或杂环芳基）较低烷基；或Rb和Rc一起代表较低烷基；以及其药学上可接受的盐；以及其对映体；它们可用作微粒体三酰甘油转移蛋白（MTP）和载脂蛋白B（apoB）分泌的抑制剂。
• Use of therapeutic benzamide derivatives
  申请人：——

  公开号：US20040044008A1

  公开（公告）日：2004-03-04

  The invention relates to the use of therapeutic benzamide compounds of formula (I). As microsomal triglyceride transfer protein (MTP) inhibitors for treating obesity and post-prandial hyperlipemia. 1

  本发明涉及治疗用苯甲酰胺化合物（I）的使用。作为微粒体甘油三酯转移蛋白（MTP）抑制剂，用于治疗肥胖和餐后高脂血症。
• Amino-benzocycloalkane derivatives
  申请人：Novartis AG

  公开号：US06197798B1

  公开（公告）日：2001-03-06

  Compounds of the formula I wherein R2—C, R3—C, R4—C or R5—C may be replaced by N; and wherein n is 1, 2 or 3; R1 is aryl, cycloalkyl or heterocyclyl; R2, R3, R4 and R5 are independently hydrogen, optionally substituted alkyl, halo, amino, substituted amino, trifluoromethyl, cyano, carboxyl, alkoxycarbonyl, aralkoxycarbonyl, (alkyl, aryl or aralkyl)-thio, (alkyl, aryl or aralkyl)-oxy, acyloxy, (alkyl, aryl or aralkyl)-aminocarbonyloxy; or any two of R2, R3, R4 and R5 at adjacent positions are alkylenedioxy; R6 is hydrogen, optionally substituted alkyl, amino, substituted amino, acylamino, wherein Ra is hydrogen or optionally substituted alkyl, Rb and Rc are independently hydrogen, optionally substituted alkyl, cycloalkyl, aryl or heterocyclyl; or Rb and Rc together represent lower alkylene or lower alkylene interrupted by O, S, or N—(H, alkyl or aralkyl); Rd is optionally substituted alkyl, cycloalkyl, aryl or heterocyclyl; and Re is optionally substituted alkyl, aryl, heterocyclyl, cycloalkyl, amino or substituted amino; and pharmaceutically acceptable salts thereof; and enantiomers thereof; which are useful as inhibitors of microsomal triglyceride transfer protein (MTP) and of apolipoprotein B (ApoB) secretion.

  根据您的要求，以下是公式I化合物的中文翻译： 化合物具有公式I，其中R2—C、R3—C、R4—C或R5—C可以被N取代；并且其中n为1、2或3；R1为芳基、环烷基或杂环基；R2、R3、R4和R5独立地为氢、可选地取代的烷基、卤素、氨基、取代氨基、三氟甲基、氰基、羧基、烷氧羰基、芳烷氧羰基、(烷基、芳基或芳烷基)硫基、(烷基、芳基或芳烷基)氧基、酰氧基、(烷基、芳基或芳烷基)氨基甲氧基；或者R2、R3、R4和R5中任意两个相邻位置的为烷基亚甲基二氧基；R6为氢、可选地取代的烷基、氨基、取代氨基、酰氨基，其中Ra为氢或可选地取代的烷基，Rb和Rc独立地为氢、可选地取代的烷基、环烷基、芳基或杂环基；或者Rb和Rc共同代表低碳烯基或由O、S或N—(H、烷基或芳烷基)打断的低碳烯基；Rd为可选地取代的烷基、环烷基、芳基或杂环基；Re为可选地取代的烷基、芳基、杂环基、环烷基、氨基或取代氨基；以及药用可接受的盐；以及它们的对映体；这些化合物可用作微粒体甘油三酯转移蛋白（MTP）和载脂蛋白B（ApoB）分泌的抑制剂。
• A Convenient Procedure for Parallel Ester Hydrolysis
  作者：R. Kiplin Guy、Marc O. Anderson、Jamie Moser、John Sherrill

  DOI：10.1055/s-2004-832828

  日期：——

  The treatment of alkyl esters with barium hydroxide ­octahydrate in methanol followed by protonation with anhydrous hydrogen chloride affords carboxylic acids. The procedure does not require aqueous workup and is particularly suitable for parallel ­synthesis applications.

  用八水合氢氧化钡处理烷基酯并在甲醇中用无水氢氯酸质子化，可以得到羧酸。该方法无需水洗处理，特别适用于并行合成应用。
• Cat-1 inhibitors, pharmaceutical compositions and methods of use
  申请人：Hoffman-La Roche Inc.

  公开号：US05344843A1

  公开（公告）日：1994-09-06

  The invention relates to compounds of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.2 ' X, Y, Z, A, B, Q and n are as described herein. Their pharmaceutically acceptable salts, and when appropriate, enantiomers, racemates, diastereomers or mixtures thereof or geometric isomer or mixtures thereof, and pharmaceutically acceptable salts thereof. The compounds of formula I inhibit enzyme carnitine acyltransferase 1 (CAT-1) and are therefore useful in the prevention of injury to ischemic tissue, and can limit infarct size, improve cardiac function and prevent arrhythmias during and following a myocardial infarction.

  该发明涉及以下式的化合物：##STR1## 其中R.sub.1、R.sub.2、R.sub.2'、X、Y、Z、A、B、Q和n如本文所述。它们的药学上可接受的盐，必要时，对映体、拉克酸盐、异构体或其混合物或几何异构体或其混合物，以及其药学上可接受的盐。式I的化合物抑制酶肉碱酰转移酶1（CAT-1），因此在预防缺血组织损伤方面非常有用，并且可以限制梗死面积，改善心脏功能，并在心肌梗死期间和随后防止心律失常。